Presentation of Clinical Data, FDA Approval, Notes Offering, and Market Activity - Research Reports on Biogen Idec, Arrowhead, Salix, HCA and Shire

NEW YORK, October 13, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Biogen Idec Inc. (NASDAQ: BIIB), Arrowhead Research Corp. (NASDAQ: ARWR), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), HCA Holdings, Inc. (NYSE: HCA) and Shire plc (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7111-100free.

--
Biogen Idec Inc. Research Reports
On October 8, 2014, the stock of Biogen Idec Inc. (Biogen Idec) gained 2.74% to close at $324.59, in-line with the broad market rally after U.S. Federal Open Market Committee's meeting minutes suggested that interest rates will stay near zero for a considerable time. Shares in Biogen Idec opened at $315.66, and traded in the range of $312.00 - $325.78, with a total of 1.28 million shares changing hands. The Nasdaq Biotechnology Index gained 2.90% during the session. The stock remained above its 200-day moving average of $315.21, which was below its 50-day moving average of $332.27. The full research reports on Biogen Idec are available to download free of charge at:

http://www.analystsreview.com/Oct-13-2014/BIIB/report.pdf

--
Arrowhead Research Corp. Research Reports
On October 8, 2014, Arrowhead Research Corp. (Arrowhead) announced that data from the ongoing Phase 2a study of ARC-520, its RNAi therapeutic candidate for the treatment of chronic hepatitis B (HBV) infection, will be presented in the late-breaking poster session at the 2014 American Association for the Study of Liver Diseases (AASLD) Liver Meeting, to be held from November 7- November 11, 2014, in Boston. "Our ongoing Phase 2a dose finding study is an important step, and in cohort 1 at a dose of 1 mg/mg and cohort 2 at 2 mg/kg we saw a clear reduction in HBsAg, the surface antigen of HBV. Data collection for HBsAg reduction in cohort 3 at 3 mg/kg is still ongoing, however we are pleased to report that all three dose levels have been well tolerated in patients," said Christopher Anzalone, Ph.D., Arrowhead's President and CEO. However, on the same day, shares of the Company plunged 43.80% to close at $7.03. According to a report by MarketWatch, the Company's stock declined as data fell short of market expectations. The full research reports on Arrowhead are available to download free of charge at:

http://www.analystsreview.com/Oct-13-2014/ARWR/report.pdf

--
Salix Pharmaceuticals Ltd. Research Reports
On October 8, 2014, Salix Pharmaceuticals Ltd. (Salix) announced that the U.S. Food and Drug Administration (FDA) has granted final approval to UCERIS (budesonide) rectal foam for the induction of remission in patients with active mild-to-moderate distal ulcerative colitis (UC) extending up to 40cm from the anal verge. Salix stated that UCERIS received tentative approval from the FDA on September 15, 2014 pending expiration of the 45-day waiting period which expired on October7, 2014. According to the Company, the Crohn's and Colitis Foundation of America (CCFA) estimates that UC may affect as many as 700,000 Americans. The full research reports on Salix are available to download free of charge at:

http://www.analystsreview.com/Oct-13-2014/SLXP/report.pdf

--
HCA Holdings, Inc. Research Reports
On October 7, 2014, HCA Holdings, Inc. (HCA) announced that its wholly owned subsidiary, HCA Inc., proposes to offer senior secured notes worth $1.5 billion. According to the Company, HCA Inc. intends to use the issue proceeds to redeem and repurchase all of the $1.4 billion aggregate principal amount outstanding of 7 ¼% senior secured notes due 2020, to pay related fees and expenses and for general corporate purposes. The Company added that actual terms of the notes will depend on market conditions at the time of pricing. BofA Merrill Lynch, Barclays, Citigroup, Credit Suisse, Deutsche Bank Securities, Goldman, Sachs & Co., J.P. Morgan, Morgan Stanley, RBC Capital Markets, SunTrust Robinson Humphrey, UBS Investment Bank and Wells Fargo Securities are acting as the joint book-running managers for the offering. The full research reports on HCA are available to download free of charge at:

http://www.analystsreview.com/Oct-13-2014/HCA/report.pdf

--
Shire plc Research Reports
On October 9, 2014, Shire plc (Shire) announced that the U.S. Food and Drug Administration (FDA) has clarified that additional pediatric data would be required for resubmission of SHP 465, an investigational oral stimulant medication being evaluated as a potential treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in adults. In April this year, FDA had told Shire that it could submit SHP 465 as a Class 2 resubmission. Shire informed that this clarification came after series of follow-up discussions with FDA, and will impact the Company's plan for a 2014 New Drug Application (NDA) resubmission for SHP 465. Shire said that SHP 465 has the potential to be an important treatment option for adults with ADHD. The full research reports on Shire are available to download free of charge at:

http://www.analystsreview.com/Oct-13-2014/SHPG/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review